Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities
Hua-ying Li,Yi-li Chen,Xiang-nan Deng,Huan-huan Li,Jie Tan,Guo-jian Liu,Yu-juan Zheng,Min Pei,Kai-ting Peng,Li-li Yue,Xiao-jia Chen,Yu Liu,Yong-shan Zhao,Chun-he Wang
DOI: https://doi.org/10.1038/s41401-023-01118-2
IF: 7.169
2023-06-17
Acta Pharmacologica Sinica
Abstract:Clinical application of PD-1 and PD-L1 monoclonal antibodies (mAbs) is hindered by their relatively low response rates and the occurrence of drug resistance. Co-expression of B7-H3 with PD-L1 has been found in various solid tumors, and combination therapies that target both PD-1/PD-L1 and B7-H3 pathways may provide additional therapeutic benefits. Up to today, however, no bispecific antibodies targeting both PD-1 and B7-H3 have reached the clinical development stage. In this study, we generated a stable B7-H3×PD-L1 bispecific antibody (BsAb) in IgG1-VHH format by coupling a humanized IgG1 mAb against PD-L1 with a humanized camelus variable domain of the heavy-chain of heavy-chain antibody (VHH) against human B7-H3. The BsAb exhibited favorable thermostability, efficient T cell activation, IFN-γ production, and antibody-dependent cell-mediated cytotoxicity (ADCC). In a PBMC humanized A375 xenogeneic tumor model, treatment with BsAb (10 mg/kg, i.p., twice a week for 6 weeks) showed enhanced antitumor activities compared to monotherapies and, to some degree, combination therapies. Our results suggest that targeting both PD-1 and B7-H3 with BsAbs increases their specificities to B7-H3 and PD-L1 double-positive tumors and induces a synergetic effect. We conclude that B7-H3×PD-L1 BsAb is favored over mAbs and possibly combination therapies in treating B7-H3 and PD-L1 double-positive tumors.
pharmacology & pharmacy,chemistry, multidisciplinary